2′-O-(2-Methoxyethyl) Nucleosides Are Not Phosphorylated or Incorporated Into the Genome of Human Lymphoblastoid TK6 Cells

5-Formylcytosine Could Be a Semipermanent Base in Specific Genome Sites

(2016) Meng Su et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Standardized cell sources and recommendations for good cell culture practices in genotoxicity testing

(2016) E. Lorge et al.   MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS

Oligonucleotide-based theranostic nanoparticles in cancer therapy

(2016) Reza Shahbazi et al.   Nanomedicine

Synthesis of (R)-Configured 2′-Fluorinated mC, hmC, fC, and caC Phosphoramidites and Oligonucleotides

(2016) Arne S. Schröder et al.   ORGANIC LETTERS

OSWG Recommendations for Genotoxicity Testing of Novel Oligonucleotide-Based Therapeutics

(2016) Cindy L. Berman et al.   Nucleic Acid Therapeutics

Exposure to siRNA-GalNAc Conjugates in Systems of the Standard Test Battery for Genotoxicity

(2016) Maja M. Janas et al.   Nucleic Acid Therapeutics

2′-Fluoro-modified phosphorothioate oligonucleotide can cause rapid degradation of P54nrb and PSF

(2015) Wen Shen et al.   NUCLEIC ACIDS RESEARCH

5-Hydroxymethylcytosine is a predominantly stable DNA modification

(2014) Martin Bachman et al.   Nature Chemistry

Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B

(2012) Stanley T. Crooke et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Designing Chemically Modified Oligonucleotides for Targeted Gene Silencing

(2012) Glen F. Deleavey et al.   CHEMISTRY & BIOLOGY

An Overview of Sugar-Modified Oligonucleotides for Antisense Therapeutics

(2011) Thazha P. Prakash   CHEMISTRY & BIODIVERSITY

RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform

(2010) C. Frank Bennett et al.   Annual Review of Pharmacology and Toxicology

Chemically modified siRNA: tools and applications

(2008) J WATTS et al.   DRUG DISCOVERY TODAY